Last updated: September 1, 2026
Cimetidine hydrochloride is a mature, off-patent H2-receptor antagonist with limited commercial growth potential. Its original product, Tagamet, generated major revenue for SmithKline Beecham in the 1980s, but patent expiry and competition from ranitidine, famotidine, proton-pump inhibitors, and OTC alternatives sharply reduced its value. Current demand is concentrated in low-cost generic tablets, oral solutions, and injectable hospital products. Public companies generally do not report cimetidine hydrochloride revenue separately.
What is cimetidine hydrochloride and how is it used?
Cimetidine hydrochloride is the hydrochloride salt of cimetidine, an H2-receptor antagonist that reduces gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells. The product has been used for duodenal and gastric ulcers, gastroesophageal reflux disease, pathological hypersecretory conditions, and selected inpatient acid-suppression indications.[1]
The salt form is particularly relevant to injectable products. Many oral products are described commercially as cimetidine rather than cimetidine hydrochloride, even though the active pharmaceutical ingredient can be manufactured through a salt-form process.
Main dosage forms
| Dosage form |
Typical commercial role |
Current market position |
| Tablets |
Chronic outpatient treatment and OTC use |
Low-cost generic product |
| Oral solution or liquid |
Pediatric and swallowing-limited patients |
Niche generic demand |
| Injection |
Hospital and institutional use |
Limited, supply-sensitive market |
| Combination products |
Historical OTC and prescription use |
Commercially marginal |
Cimetidine is less attractive than newer acid-suppression therapies because of its extensive cytochrome P450 drug-interaction profile. It can inhibit metabolism of medicines including warfarin, phenytoin, theophylline, diazepam, and selected calcium-channel blockers.[1] That interaction burden has constrained use even where the drug remains clinically effective.
When did cimetidine lose exclusivity?
Cimetidine lost meaningful U.S. market exclusivity in the 1990s. The original Tagamet patent estate was associated with SmithKline, the predecessor to later GlaxoSmithKline corporate structures. The principal U.S. compound patent was US Patent No. 3,950,333, which covered cimetidine and related compounds. The patent expired after the relevant term and extensions, allowing generic competition.[2]
Cimetidine exclusivity timeline
| Period |
Commercial event |
Market effect |
| 1970s |
SmithKline develops and launches Tagamet |
First major H2-blocker commercial success |
| 1977 |
FDA approves Tagamet for ulcer treatment |
Prescription market established |
| Early 1980s |
Tagamet becomes a blockbuster product |
Annual sales reach approximately $1 billion at peak, according to historical industry accounts |
| Mid-to-late 1980s |
Ranitidine and other H2 blockers gain share |
Price and volume pressure begins |
| Early 1990s |
Core U.S. patent protection expires |
Generic entry accelerates |
| 1990s |
OTC conversion and broader generic availability |
Brand value declines |
| 2000s onward |
PPIs dominate acid-suppression treatment |
Cimetidine becomes a mature, low-value product |
The exact commercial peak varies by reporting year and source. Public historical accounts generally place Tagamet sales near or above $1 billion annually before generic erosion.[3]
What patents protect cimetidine hydrochloride?
No commercially meaningful U.S. composition-of-matter patent protection remains for cimetidine hydrochloride. The original compound patents, formulation rights, and standard method-of-use claims are long expired.
Historical patent estate
The original estate generally covered:
- The cimetidine compound and related imidazole derivatives.
- Pharmaceutical compositions containing cimetidine.
- Treatment of acid-related gastrointestinal disorders.
- Manufacturing routes and intermediates.
- Selected dosage forms and injectable presentations.
US Patent No. 3,950,333 is the key historical compound patent commonly associated with cimetidine.[2] Any surviving rights would be expected to concern narrow manufacturing, formulation, or jurisdiction-specific claims rather than broad exclusivity over cimetidine hydrochloride.
Current patent strength
| Patent category |
Current strength in the United States |
Commercial implication |
| Compound patent |
None |
No barrier to generic API or finished-dose entry |
| Basic oral formulation |
None or immaterial |
Multiple generic alternatives possible |
| Standard injectable formulation |
Weak |
Supply-chain and regulatory barriers matter more |
| Method of use |
Expired or commercially weak |
Limited differentiation |
| Manufacturing process |
Potentially narrow and jurisdiction-specific |
May affect individual suppliers, not the market broadly |
| Device or delivery technology |
Minimal relevance |
No major branded delivery platform |
The remaining competitive barriers are primarily regulatory, manufacturing, quality, and distribution barriers. They are not broad exclusivity rights.
What is the FDA regulatory status of cimetidine hydrochloride?
Cimetidine is an established FDA-approved active ingredient. Prescription and OTC products have been marketed in the United States for decades. FDA-approved labeling covers cimetidine tablets, oral products, and injectable presentations, subject to the status of individual products and manufacturers.[1]
The principal regulatory issues are:
- Drug-drug interactions caused by CYP450 inhibition.
- Dose adjustment in renal impairment.
- Central nervous system effects in older or medically fragile patients.
- Differentiation between prescription and OTC labeling.
- Product-specific availability of injectable presentations.
Cimetidine has no biosimilar pathway because it is a small-molecule drug, not a biologic. Generic entrants use the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence where applicable.
What is the Orange Book status of cimetidine?
Cimetidine products may appear in the FDA Orange Book through individual abbreviated or full new drug applications, but Orange Book status is product-specific and changes as manufacturers discontinue, transfer, or withdraw products.[4]
The original Tagamet listing does not create an active market barrier comparable to a current patented reference product. Any listed patents associated with legacy branded products are expired or otherwise commercially irrelevant to ordinary generic entry. The practical market question is whether an approved generic product remains active and commercially supplied, not whether the historic brand once had Orange Book patents.
Paragraph IV challenges
Paragraph IV litigation was commercially important when generic manufacturers first challenged Tagamet-related patents. It has little current relevance because the core patent estate expired decades ago. New cimetidine hydrochloride ANDA filings would generally face a mature product landscape rather than an active branded patent-defense campaign.
No current, high-value Paragraph IV dispute is widely associated with cimetidine hydrochloride. A supplier could still face regulatory correspondence, manufacturing observations, product-quality actions, or ordinary ANDA litigation, but those events would not recreate the original exclusivity structure.
How has the cimetidine market changed?
The market moved through four distinct phases.
1. Innovation and premium pricing
Tagamet entered a market in which ulcer treatment relied heavily on antacids, anticholinergic agents, and surgical intervention. Cimetidine offered a pharmacologically targeted approach and rapidly gained physician adoption. The product supported premium prescription pricing and large sales-force investment.
2. H2-blocker competition
Ranitidine, marketed as Zantac, became the most important direct competitor. Famotidine, marketed as Pepcid, later added further pressure. These products offered similar acid suppression, with famotidine generally viewed as having fewer clinically significant drug interactions than cimetidine.[5]
3. Generic erosion
After patent expiry, generic cimetidine entered at substantially lower prices. Pharmacy benefit managers and wholesalers treated cimetidine as a commodity product. Brand retention became difficult except in segments with established physician familiarity or OTC recognition.
4. PPI substitution
Omeprazole, lansoprazole, pantoprazole, and other PPIs displaced H2 blockers in many higher-value treatment categories. PPIs generally provide stronger and longer acid suppression, particularly for erosive esophagitis and more severe reflux disease.[6]
How does cimetidine compare with famotidine and proton-pump inhibitors?
| Attribute |
Cimetidine |
Famotidine |
Proton-pump inhibitors |
| Drug class |
H2 antagonist |
H2 antagonist |
Acid pump inhibitor |
| Market maturity |
Very mature |
Mature |
Mature but commercially larger |
| Drug interactions |
Relatively high |
Lower than cimetidine |
Product-specific |
| Acid suppression |
Moderate |
Moderate to strong within class |
Generally stronger |
| Generic competition |
Extensive |
Extensive |
Extensive |
| Commercial growth |
Minimal |
Limited |
Higher historical value |
| Hospital use |
Selective |
More commonly preferred H2 option |
Broad |
| Patent value |
Expired |
Core patents expired or near-expired depending on product |
Product-specific and often formulation-driven |
Famotidine is the closest practical substitute in the H2-blocker category. PPIs are the more important therapeutic substitute in the overall acid-suppression market.
What is the financial trajectory of cimetidine hydrochloride?
Cimetidine’s financial trajectory is a classic innovator-to-commodity cycle.
| Stage |
Revenue profile |
Margin profile |
Main driver |
| Launch |
Rapid growth |
High |
Clinical differentiation |
| Blockbuster period |
Approximately $1 billion annual Tagamet sales at peak |
High |
First-mover advantage and prescription demand |
| Competitive erosion |
Declining sales |
Falling |
Ranitidine and famotidine |
| Patent expiry |
Sharp revenue reduction |
Compressed |
Generic substitution |
| Mature generic period |
Low and fragmented |
Low to moderate for efficient manufacturers |
Volume, shortages, contracts, and API cost |
The original brand generated substantial revenue, but cimetidine hydrochloride no longer supports a material branded pharmaceutical franchise. Current revenue is distributed among generic manufacturers, contract suppliers, hospital distributors, and retailers. Most companies do not disclose product-level sales because cimetidine is immaterial within their portfolios.
Revenue exposure for manufacturers
For a generic manufacturer, cimetidine can provide:
- Incremental revenue from an established product.
- A low-development-cost addition to a hospital or primary-care portfolio.
- Portfolio depth for distributors and group purchasing organizations.
- Occasional pricing opportunities during supply interruptions.
It does not generally provide:
- Durable pricing power.
- Meaningful patent-based exclusivity.
- A high-growth market.
- A strategic platform for follow-on innovation.
The strongest financial opportunity is episodic. If one or more suppliers exit, remaining manufacturers can experience temporary volume or price increases. Those gains depend on inventory, API access, manufacturing capacity, and FDA compliance.
What generic entry risks exist for cimetidine hydrochloride?
Generic entry risk is structurally high because the core intellectual property has expired. The main risk for an incumbent is not a single competitor but cumulative substitution across pharmacies, hospitals, wholesalers, and online channels.
Key competitive risks
- Additional ANDA approvals can increase price pressure.
- Large buyers can consolidate purchases among a small number of suppliers.
- Low demand can cause manufacturers to discontinue products.
- API disruptions can create short-term shortages.
- Injectable products face greater quality and supply-chain sensitivity than tablets.
- Famotidine and PPIs can reduce clinical demand even when cimetidine pricing is low.
For buyers, the product may be inexpensive but operationally fragile if only a few approved suppliers remain active.
What manufacturing and intellectual-property barriers remain?
Cimetidine hydrochloride has no broad IP barrier comparable to a new chemical entity. Manufacturing barriers are more relevant.
API and finished-dose considerations
Manufacturers must control:
- Starting-material quality.
- Impurity profiles and residual solvents.
- Salt formation and crystallization.
- Stability through shelf life.
- Injectable sterility and particulate limits.
- Container-closure compatibility.
- Bioequivalence for oral products.
- Consistency across approved manufacturing sites.
The injectable product is commercially more sensitive because sterile manufacturing capacity is limited and remediation can take longer than for conventional tablets. This can create temporary supply scarcity without creating durable market power.
What patent litigation and settlement agreements affect the market?
Historical litigation centered on generic challenges to Tagamet patents and on competition among H2-blocker manufacturers. Those disputes shaped the transition from branded exclusivity to generic supply.
Current litigation risk is low relative to active patented drugs. No widely recognized settlement agreement presently gives cimetidine hydrochloride a meaningful period of market exclusivity. Any historical settlement would have little ability to restrict current generic entry after expiration of the underlying patent terms.
What geographic coverage exists for cimetidine hydrochloride?
Cimetidine has broad historical regulatory coverage across the United States, Europe, and other major pharmaceutical markets. Patent protection has expired in the principal jurisdictions. Current commercial availability varies by country because companies may discontinue low-volume presentations, particularly injectables.
| Region |
IP position |
Market condition |
| United States |
Core patents expired |
Generic and institutional market |
| European Union |
Core patents expired |
Country-specific generic availability |
| Japan |
Core patents expired |
Mature prescription market |
| Emerging markets |
Generally off-patent |
Local generic and tender-driven supply |
| Hospital markets globally |
No broad patent barrier |
Availability depends on sterile capacity and procurement |
How strong is the commercial case for cimetidine hydrochloride?
The commercial case is defensive rather than growth-oriented. Cimetidine hydrochloride is suitable for manufacturers with existing API capacity, established regulatory files, and distribution into hospitals or generic pharmacies. It is less attractive as a standalone development project because demand is mature and competing therapies are widely available.
A rational valuation should focus on:
- Approved market share.
- Number of active competitors.
- Historical shortage frequency.
- Contracted hospital volume.
- API cost and supplier concentration.
- Injectable versus oral mix.
- Product discontinuation risk.
- Country-specific reimbursement and procurement rules.
Patent-based valuation should be close to zero for the core active ingredient. Any premium would need to come from manufacturing reliability, supply contracts, regulatory approvals, or temporary market concentration.
Key Takeaways
- Cimetidine hydrochloride is an established, off-patent H2-receptor antagonist.
- Tagamet generated approximately $1 billion in annual sales at its historical peak, but that revenue was lost through competition and patent expiry.
- The core cimetidine patent estate, including US Patent No. 3,950,333, is expired.
- No biosimilar issue applies because cimetidine is a small molecule.
- Paragraph IV litigation is no longer a central market factor.
- Famotidine and PPIs are the principal therapeutic competitors.
- Current revenue is generic, fragmented, and generally not disclosed at the product level.
- Injectable supply and manufacturing capacity can create short-term commercial opportunities.
- Long-term pricing power and patent-based exclusivity are absent.
- The product is most valuable as a portfolio or hospital-supply product, not as a growth asset.
FAQs About Cimetidine Hydrochloride
Is cimetidine hydrochloride still commercially available?
Yes. Availability depends on country, dosage form, manufacturer, and whether the product is prescription, OTC, or hospital injectable.
Does cimetidine hydrochloride have active U.S. patent protection?
No broad composition-of-matter protection remains. Any surviving rights would likely be narrow and product-specific rather than capable of blocking ordinary generic entry.
Is cimetidine hydrochloride more profitable than famotidine?
Generally no. Famotidine has stronger clinical positioning because of its lower interaction burden, while both products face generic competition. Profitability depends on supplier concentration and dosage form.
Can a company obtain market exclusivity for a new cimetidine formulation?
A genuinely novel formulation could potentially receive patent protection or regulatory exclusivity if it satisfies applicable legal requirements. A conventional tablet, solution, or injectable presentation is unlikely to create meaningful new exclusivity by itself.
Why did cimetidine lose market share despite being effective?
The product faced two pressures: newer H2 blockers with more favorable interaction profiles and PPIs with stronger acid suppression. Generic price erosion then reduced the commercial value of the remaining demand.
References
-
U.S. Food and Drug Administration. (n.d.). Cimetidine prescribing information. FDA-approved drug labeling and DailyMed records.
-
U.S. Patent and Trademark Office. (1976). U.S. Patent No. 3,950,333: Cimetidine and related compounds. Washington, DC: U.S. Department of Commerce.
-
SmithKline Beecham plc. (1997). Annual report and historical product information. London: SmithKline Beecham.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. National Library of Medicine. (n.d.). Cimetidine and famotidine drug information. MedlinePlus and DailyMed.
-
Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022). ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 117(1), 27-56.
